{"id":60745,"title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.","abstract":"","date":"2014-06-27","categories":"Hemic and Lymphatic Diseases","split":"train","url":"http://www.ncbi.nlm.nih.gov/pubmed/24833354","annotations":[{"name":"Randomization","weight":0.341689,"wikipedia_article":"http://en.wikipedia.org/wiki/Randomization"},{"name":"Randomized controlled trial","weight":0.041711,"wikipedia_article":"http://en.wikipedia.org/wiki/Randomized_controlled_trial"},{"name":"Multiple myeloma","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Multiple_myeloma"},{"name":"Phase (waves)","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(waves)"},{"name":"PHASE 2","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/PHASE_2"}]}
